Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia

Expert Opinion on Drug Safety

Volumn 14, Issue 8, 2015, Pages 1237-1247

  Liapikou, Adamantia ^a   Toumbis, Michael ^a   Torres, Antoni ^b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Long acting agonists; Mortality; Pneumonia

Indexed keywords

CORTICOSTEROID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID;

BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG SAFETY; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SMOKING; VACCINATION; ANIMAL; CHEMICALLY INDUCED; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

EID: 84937205442     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1057494     Document Type: Review

References (78)

1. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www. goldcopd. org/uploads/users/ files/GOLD-Report-2015-Apr2. pdf [Last accessed 2015]
2. Mapel DW, Hurley JS, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006;100:595-609
3. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26
4. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184(6):662-71
5. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and shortterm response to prednisolone in chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2000;356:1480-5
6. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 2007;29(5):906-13
7. Hospers JJ, Schouten JP, Weiss ST, et al. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 1999;160:1869-74
8. Chung KF. Salmeterol/fluticasone combination in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2006;1(3):235-42
9. Burgel PR, Deslee G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: A paradigm shift in GOLD 2011? Eur Respir J 2014;43:1201-3
10. Farr BM, Bartlett CL, Wadsworth J, et al. Risk factors for communityacquired pneumonia diagnosed upon hospital admission. Respir Med 2000;94(10):954-63
11. Gau JT, Acharya U, Khan S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010;10:45
12. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346-51
13. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417-24
14. Ernst P, González AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176(2):162-6
15. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/ salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108
16. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: A critical review and update. Curr Opin Pulm Med 2010;16(2):118-22
17. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: A meta-analysis of individual patient data. Lancet 2009;374(9691):712-19
18. Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/ fluticasone in COPD: A systematic review and adjusted indirect comparison of pneumonia in randomized controlled trials. Int J Clin Pract 2011;65:764-74
19. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of communityacquired pneumonia in COPD patients: A population database analysis. Respir Med 2012;106(8):1124-33
20. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: A meta-analysis. Arch Intern Med 2009;169(3):219-29
21. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 2008;300(20):2407-16
22. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomized placebocontrolled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD study group. Lancet 1998;351:773-80
23. Pauwels RA, Lofdahl CG, Laitinen LA, et al. European respiratory society study on chronic obstructive pulmonary disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53
24. Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 1999;353:1819-23
25. DiSantostefano RL, Sampson T, Le HV, et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: A newuser cohort study. PLoS One 2014;9(5):e97149
26. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
27. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7
28. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139(3):505-12
29. Almirall J, Bolbar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010;36(5):1080-7
30. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids and the risk of serious pneumonia. Thorax 2013;68:10129-36
31. Festic E, Bansal V, Gajic O, et al. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014;89:154-62
32. Mapel D, Schum M, Yood M, et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 2010;19(2):109-17
33. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115
34. Woodhead M. Inhaled corticosteroids cause pneumonia or do they? Am J Respir Crit Care Med 2007;176(2):111-12
35. Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36-41
36. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312-16
37. Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855-61
38. Sellares J, Lopez-Giraldo A, Lucena C, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013;187(11):1241-8
39. Men-endez R, Torres A, Zalacán R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59(11):960-5
40. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir Med 2013;1(3):210-23
41. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(2):144-9
42. Loke YK, Kwok CS, Wong JM, et al. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract 2013;67(5):477-87
43. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26
44. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
45. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur Respir J 2010;36:751-7
46. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104(2):246-52
47. Guti-errez P, Closa D, Piner R, et al. Macrophage activation in exacerbated COPD with and without communityacquired pneumonia. Eur Respir J 2010;36(2):285-91
48. Barbier M, Agust A, Alberti S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008;32(5):1283-8
49. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/ salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-9
50. Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:469-88
51. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176(5):454-9
52. Finney L, Berry M, Singanayagam A, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med 2014;2:919-32
53. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45(2):525-37
54. Keene ON, Vestbo J, Anderson JA, et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J 2009;34:1018-23
55. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999;159:941-55
56. Sibila O, Laserna E, Mortensen EM, et al. Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance. Respir Care 2013;58(9):1489-94
57. Patterson CM, Morrison RL, D'Souza A, et al. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res 2012;13:40
58. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71
59. Marin A, Garcia-Aymerich J, Sauleda J, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012;9:121-30
60. Miravitlles M, Marin A, Monso E, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010;11:58
61. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;67:1075-80
62. Marin A, Monso E, Garcia-Nunez M, et al. Variability and effects of bronchial colonization in patients with moderate COPD. Eur Respir J 2010;35(2):295-302
63. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010;340:c2096
64. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: www. ginasthma. org/local/uploads/files/GINA- Report-2014-Aug12. pdf [Last accessed 12 August 2014]
65. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: A novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531-9
66. Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995;108:1568-71
67. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71
68. Brightling CE, McKenna S, Hardagon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pumonary disease. Thorax 2005;60:193-8
69. Marc M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol 2011;47(6):271-3
70. Lee JH, Lee YK, Kim EK, et al. Responses to inhaled long-acting betaagonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9
71. Nair P. Update on clinical inflammometry for the management of airway diseases. Can Respir J 2013;20:117-20
72. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;34:812-18
73. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12(1):27-34
74. Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6
75. Magnussen H, Watz H, Kirsten A, et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med 2014;108(4):593-9
76. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371(14):1285-94
77. Miravitlles M, Soler-Catalunã JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish society of pulmonology and thoracic surgery. Arch Bronconeumol 2012;48(7):247-57
78. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011;183(5):589-95